Peer-reviewedCC BY 4.0eJHaem
Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
Abstract
This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer-BioNTech) in 112 Allo-HSCT patients. Antibody response to SARS-CoV-2 spike protein receptor-binding domain was tested at the time of the second injection (Roche Elecsys). The study also included a non-randomized control arm of 26 healthy controls. This study shows that a first dose of SARS-CoV-2 messenger RNA vaccine is safe and provides a 55% rate of seroconversion in allotransplanted patients compared to 100% for the controls (p < 0.001). Factors influencing the absence of response in patients were recent transplantation (<2 years), lymphopenia (<1 × 10 9 /L) and immunosuppressive treatment or chemotherapy at the time of vaccination.
Related
- Surveillance of CMV Terminase Gene Mutations in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis
- Incidence and Outcomes of Human Adenovirus Infection and Disease in a Multicenter Cohort of Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
- Deep immune cell phenotyping predicts influenza vaccine immunogenicity in HCT recipients
- Immunogenicity and safety of Sabin inactivated poliovirus vaccine in a sequential schedule with bivalent oral poliovirus vaccine in Nepal: a single-centre, double-blind, randomised, controlled, non-inferiority trial
- 531 Phase I study to assess the safety, immunogenicity, and preliminary antitumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with R/R lymphoma
BibTeX
@article{chevallier2026safety,
title = {{Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients}},
author = {Patrice Chevallier and Marianne Coste‐burel and Amandine Le Bourgeois and Pierre Peterlin and Alice Garnier and Marie C Béné and Berthe‐marie Imbert and Thomas Drumel and Steven Le Gouill and Philippe Moreau and Beatrice Mahe and Viviane Dubruille and Nicolas Blin and Anne Lok and Cyrille Touzeau and Thomas Gastinne and Maxime Jullien and Sophie Vanthygem and Thierry Guillaume},
journal = {eJHaem},
year = {2026},
month = sep,
doi = {10.1002/jha2.242},
url = {https://hal.science/hal-05753598v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
AU - Patrice Chevallier
AU - Marianne Coste‐burel
AU - Amandine Le Bourgeois
AU - Pierre Peterlin
AU - Alice Garnier
AU - Marie C Béné
AU - Berthe‐marie Imbert
AU - Thomas Drumel
AU - Steven Le Gouill
AU - Philippe Moreau
AU - Beatrice Mahe
AU - Viviane Dubruille
AU - Nicolas Blin
AU - Anne Lok
AU - Cyrille Touzeau
AU - Thomas Gastinne
AU - Maxime Jullien
AU - Sophie Vanthygem
AU - Thierry Guillaume
PY - 2026
DA - 2026/09/17
JO - eJHaem
DO - 10.1002/jha2.242
UR - https://hal.science/hal-05753598v1
AB - This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer-BioNTech) in 112 Allo-HSCT patients. Antibody response to SARS-CoV-2 spike protein receptor-binding domain was tested at the time of the second injection (Roche Elecsys). The study also included a non-randomized control arm of 26 healthy controls. This study shows that a first dose of SARS-CoV-2 messenger RNA vaccine is safe and provides a 55% rate of seroconversion in allotransplanted patients compared to 100% for the controls (p < 0.001). Factors influencing the absence of response in patients were recent transplantation (<2 years), lymphopenia (<1 × 10 9 /L) and immunosuppressive treatment or chemotherapy at the time of vaccination.
SN - 2688-6146
ER -